<?xml version="1.0" encoding="UTF-8"?>
<ref id="B36-marinedrugs-17-00373">
 <label>36.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Marty</surname>
    <given-names>F.M.</given-names>
   </name>
   <name>
    <surname>Vidal-Puigserver</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Clark</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Gupta</surname>
    <given-names>S.K.</given-names>
   </name>
   <name>
    <surname>Merino</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Garot</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Chapman</surname>
    <given-names>M.J.</given-names>
   </name>
   <name>
    <surname>Jacobs</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Rodriguez-Noriega</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Husa</surname>
    <given-names>P.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: An international, randomised, double-blind, double-dummy, phase 3 trial</article-title>
  <source>Lancet Respir. Med.</source>
  <year>2017</year>
  <volume>5</volume>
  <fpage>135</fpage>
  <lpage>146</lpage>
  <pub-id pub-id-type="doi">10.1016/S2213-2600(16)30435-0</pub-id>
  <pub-id pub-id-type="pmid">28094141</pub-id>
 </element-citation>
</ref>
